Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Clicks: 249
ID: 269037
2014
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
65.0
/100
249 views
199 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
As compared with MPT, continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible f ā¦Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.